Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Sirturo in combination with background multidrug-resistant tuberculosis therapy in pediatric patients
2014-003372-23Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bedaquiline in multidrug-resistant tuberculosis (MDR-TB) and pulmonary tuberculosis (TB), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with adverse events or serious adverse events.
02
Drugs
bedaquiline
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2014-003372-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003372-23.